FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism

Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

(2014) Thomas O. Carpenter et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients

(2014) Hsin-Hung Lin et al.   NEPHROLOGY

Therapeutic management of hypophosphatemic rickets from infancy to adulthood

(2014) Agnès Linglart et al.   Endocrine Connections

Exploring mechanisms of FGF signalling through the lens of structural biology

(2013) Regina Goetz et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia

(2013) Ai-Luen Wu et al.   PLoS One

Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion

(2013) Hannes Olauson et al.   PLoS Genetics

Chronic Inhibition of ERK1/2 Signaling Improves Disordered Bone and Mineral Metabolism in Hypophosphatemic (Hyp) Mice

(2012) Martin Y. H. Zhang et al.   ENDOCRINOLOGY

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets

(2012) Simon Wöhrle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality

(2012) Victoria Shalhoub et al.   JOURNAL OF CLINICAL INVESTIGATION

Fibroblast growth factor 23 as a phosphotropic hormone and beyond

(2011) Seiji Fukumoto et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice

(2011) Daniel Ranch et al.   JOURNAL OF BONE AND MINERAL RESEARCH

FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone

(2011) Simon Wöhrle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

FGF23 induces left ventricular hypertrophy

(2011) Christian Faul et al.   JOURNAL OF CLINICAL INVESTIGATION

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

(2011) Tamara Isakova et al.   KIDNEY INTERNATIONAL

Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice

(2010) Yukiko Aono et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease

(2010) Hisashi Hasegawa et al.   KIDNEY INTERNATIONAL

Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia*

(2009) Yukiko Aono et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients

(2009) Hirotaka Komaba et al.   KIDNEY INTERNATIONAL

Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation

(2009) R. Goetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bone as an endocrine organ

(2009) Seiji Fukumoto et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients

(2008) Itsuro Endo et al.   BONE

Anti-FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23

(2008) Yuji Yamazaki et al.   JOURNAL OF BONE AND MINERAL RESEARCH